Healthcare Business

biotech

What Celgene Now Means for Juno

As the health care sector remains hot, it is logical to expect ongoing mergers and acquisitions action to continue. Then there are the collaborative efforts within the sector that should continue. ...
Read Full Story »
biotech

Sarepta Takes Its Foot off the Gas

Considering that a Greek exit might be on the way, the broad markets have sold off a fair amount, and across the markets companies are losing out. Sarepta Therapeutics Inc. ...
Read Full Story »
145922793

Do Health Insurance Mergers Really Need to Sweat DOJ Reviews?

The world of health insurance has been marked by consolidation for years now. It is generally true that antitrust issues arise when there become only two or three choices. The ...
Read Full Story »
Pills

Is Big Pharma Advertising Getting Out of Control?

How much are big pharmaceutical companies really spending to get their drugs out there in the public eye? In 2014, these companies spent about $4.5 billion in advertising alone, notably ...
Read Full Story »
Prescription drugs

Are Cancer Drugs Becoming Too Costly for Their Effectiveness?

When the American Society of Clinical Oncology (ASCO) decided to create a rating scale for cancer drugs, it certainly must have expected to get some pushback. The group’s initial version ...
Read Full Story »
Chaparral_Supercell

Can Celladon Weather the Storm?

Celladon Corp. (NASDAQ: CLDN) has taken the long way down. Only recently has it begun to pursue options for a potential merger or sale, but it may be too late ...
Read Full Story »
Biotechnology word cloud

CAR T-Cell Stocks a Better Way to Leverage Biotech Than New 3x ETFs

If you missed the biotech run and want to try to catch the train this late in the game, it would be wise not to use the new Proshares leveraged ...
Read Full Story »
Pills

Short Sellers Become More Focused on Big Pharma

The short interest data has been released for the June 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
DNA

Short Sellers Get More Selective on Big Biotech

The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
IPO

Ritter Debuts Quietly in IPO Launch

Ritter Pharmaceuticals Inc. (NASDAQ: RTTR) is the latest company to join in on the wave of initial public offerings. In fact, there were 14 or 15 deals on deck to ...
Read Full Story »
Biotechnology word cloud

Triple Leverage ETFs Launched in Biotech

There is a new way to trade biotech out there now. For active traders and investors looking for juiced up returns in the hot biotech sector, ProShares has launched two ...
Read Full Story »
generic drugs

Oral Testosterone Pill Could Make Lipocine Worth Substantially More

Lipocine Inc. (NASDAQ: LPCN) may have a huge hit on its hands with the first swallowable oral testosterone treatment. This could revolutionize the testosterone market because users generally have to ...
Read Full Story »
Active investor

How MELA Plans to Buy XTRAC and VTRAC From PhotoMedex

Early Tuesday morning, PhotoMedex Inc. (NASDAQ: PHMD) announced that it will be selling its XTRAC and VTRAC psoriasis and vitiligo treatment businesses to MELA Sciences Inc. (NASDAQ: MELA). The price ...
Read Full Story »
IPO

Benitec From Australia Files for US IPO: Gene Silencing and Gene Therapy

Benitec Biopharma Ltd. has filed for an initial public offering in the United States. This Australian company has filed to sell American depositary shares (ADSs), with each ADS representing 20 ...
Read Full Story »
153790263

Will One of the Health Insurance Mergers Get a Cold Shoulder?

Merger talks within the health insurance sector are reaching a critical point, and it appears that there will be some major moves in the very near future. Some might equate ...
Read Full Story »